

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3627022

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SICHUAN BIOTECHNOLOGY RESEARCH CENTER	10/08/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	SUPERLAB FAR EAST LIMITED
<b>Street Address:</b>	OMC CHAMBERS, P.O. BOX 3152, ROAD TOWN
<b>City:</b>	TORTOLA
<b>State/Country:</b>	VIRGIN ISLANDS, BRITISH
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	8425896
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	docketing@kitchanlaw.com
<b>Correspondent Name:</b>	LAW OFFICES OF ALBERT WAI-KIT CHAN, PLLC
<b>Address Line 1:</b>	141-07 20TH AVENUE, WHITESTONE
<b>Address Line 2:</b>	WORLD PLAZA, SUITE 604
<b>Address Line 4:</b>	NEW YORK, NEW YORK 11357
<b>ATTORNEY DOCKET NUMBER:</b>	792-A2-PCT-US
<b>NAME OF SUBMITTER:</b>	ALBERT WAI-KIT CHAN
<b>SIGNATURE:</b>	/Albert Wai-Kit Chan/
<b>DATE SIGNED:</b>	11/20/2015
<b>Total Attachments: 6</b>	
source=792 Assignment to Superlab (2015-10-08)#page1.tif	
source=792 Assignment to Superlab (2015-10-08)#page2.tif	
source=792 Assignment to Superlab (2015-10-08)#page3.tif	
source=792 Assignment to Superlab (2015-10-08)#page4.tif	
source=792 Assignment to Superlab (2015-10-08)#page5.tif	
source=792 Assignment to Superlab (2015-10-08)#page6.tif	

**ASSIGNMENT**

In consideration of the mutual covenants herein contained and other good and valuable consideration, the mutual receipt and legal sufficiency of which are hereby acknowledged, we, the undersigned,

**Sichuan Biotechnology Research Center**, a corporation of the **People's Republic of China** having a place of business at **No. 8, Yusa Road, Chengdu, Sichuan, 610017, People's Republic of China;**

Hereby sell, assign and transfer to **Superlab Far East Limited** a corporation of the **British Virgin Islands**, having a place of business at **OMC Chambers, P.O. Box 3152, Road Town, Tortola British Virgin Islands**, and to its successors and assigns (hereinafter referred to collectively as "ASSIGNEE") the entire right, title and interest for all countries of the world, in and to any of the following:

(1) any and all inventions and discoveries which are disclosed and claimed, and any and all inventions and discoveries which are disclosed but not claimed in the patent applications identified on **Schedule A** hereto;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including but not limited to, all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) or (2) in all countries and regions, and the right to file any patent, utility model, or other applications in all countries and regions claiming the priority of any of the applications identified in paragraphs (1) or (2), including, without limitation, under the Paris Convention for the Protection of Industrial Property, the International Patent Cooperation Treaty, or any other convention, treaty, agreement, or understanding;

(4) all divisional, continuation, continuation-in-part, substitute, renewal, reissue, and reexamination of any United States patent application(s), international patent application(s), any national stages of said international application(s), and all other applications for patent or other related property rights in any and all countries which have been or shall be filed on any of the inventions and discoveries disclosed in any of the applications of foregoing paragraphs (1) to (2);

(5) all original and reissued patents, renewals and extensions of said patents, certificates of invention, utility models, industrial design protections, design patent protections, or other governmental grants or issuances that issue from any of the applications referred to herein, and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under any law permitting remedies for infringement prior to issuance of the patent;

(6) all causes of action (whether known or unknown or whether currently pending, filed, or otherwise) and other enforcement rights under, or on account of any item in any of the foregoing paragraphs (1) through (5), including, without limitation, all causes of action and other enforcement rights for (i) damages, (ii) injunctive relief, and (iii) any other remedies of any kind for past, current, and future infringement. This Assignment includes the right, in the sole discretion of the Assignee and

without any economic benefits retained to the Assignor, to bring suit to recover for past damages, to settle infringement claims, and to license said Patent Rights; and

(7) all rights to collect royalties and other payments under or on account of any item in any of the foregoing paragraphs (1) through (6).

We hereby authorize the Commissioner of Patents of the United States, and other Patent Offices to issue to said ASSIGNEE in accordance with this Assignment any and all patents on the inventions disclosed in the applications referred herein.

We hereby agree that I/we will, at any time, upon the request, but at the expense of the ASSIGNEE or its legal representatives, (i) execute all divisional, continuation, continuation-in-part, substitute, renewal, reissue, reexamination, and all other patent applications or other documents on any and all of the foregoing inventions and discoveries for the United States and all other countries; (ii) execute all rightful oaths, assignments, powers of attorney and other papers; (iii) communicate to said ASSIGNEE and its legal representatives all facts known and documents available to the undersigned relating to the foregoing inventions and the history thereof; (iv) testify in all legal proceedings, and generally do everything possible which the ASSIGNEE and its legal representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for the foregoing inventions and for vesting title to said inventions and all applications for patents or related foreign rights and all patents on said inventions, in said ASSIGNEE.

We hereby covenant with said ASSIGNEE that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

We hereby authorize ASSIGNEE or its representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

Assignor: 魏光文  
Guangwen WEI  
Chairman of Sichuan Biotechnology Research  
Center




Date: October 8, 2015

Witness: [Signature]  
(signature)

Zuoming  
(printed name of witness)

Suite 402, Yinhaixinzuo, 163 Sanshe Road, Jinjiang District, Chengdu, Sichuan, 610063, People's  
Republic of China  
(address of witness)

Assignee: 易兴旺  
Xingwang YI, General Manager  
Superlab Far East Limited



Date: October 8, 2015

Witness: [Signature]  
(signature)

Boyang Huang  
(printed name of witness)

OMC Chambers, P.O. Box 3152, Road Town, Tortola, British Virgin Islands  
(address of witness)

**SCHEDULE A**

Docket #	Title
1 792-PCT-EP	<b>RECOMBINATION SUPER COMPOUND INTERFERON USED AS HEPATITIS B SURFACE ANTIGEN AND E ANTIGEN INHIBITOR</b> , European Patent No. 1371373, previously European App'l No. 02702211.0, Filed September 25, 2003, which is a continuation-in-part of Int'l App'l No. PCT/CN02/00128, filed February 28, 2002, which claims priority of Chinese App'l. No. 01104367.9, filed February 28, 2001
2 792-PCT-EP-CH	<b>RECOMBINATION SUPER COMPOUND INTERFERON USED AS HEPATITIS B SURFACE ANTIGEN AND E ANTIGEN INHIBITOR</b> , Switzerland Patent No. 1371373, based on European Patent No. 1371373, previously European App'l No. 02702211.0, Filed September 25, 2003, which is a continuation-in-part of Int'l App'l No. PCT/CN02/00128, filed February 28, 2002, which claims priority of Chinese App'l. No. 01104367.9, filed February 28, 2001
3 792-PCT-EP-DE	<b>RECOMBINATION SUPER COMPOUND INTERFERON USED AS HEPATITIS B SURFACE ANTIGEN AND E ANTIGEN INHIBITOR</b> , German Patent No. 60234085.3, based on European Patent No. 1 371 373, previously European App'l No. 02702211.0, Filed September 25, 2003, which is a continuation-in-part of Int'l App'l No. PCT/CN02/00128, filed February 28, 2002, which claims priority of Chinese App'l. No. 01104367.9, filed February 28, 2001
4 792-PCT-EP-FR	<b>RECOMBINATION SUPER COMPOUND INTERFERON USED AS HEPATITIS B SURFACE ANTIGEN AND E ANTIGEN INHIBITOR</b> , French Patent No. 1371373, based on European Patent No. 1 371 373, previously European App'l No. 02702211.0, Filed September 25, 2003, which is a continuation-in-part of Int'l App'l No. PCT/CN02/00128, filed February 28, 2002, which claims priority of Chinese App'l. No. 01104367.9, filed February 28, 2001
5 792-PCT-EP-GB	<b>RECOMBINATION SUPER COMPOUND INTERFERON USED AS HEPATITIS B SURFACE ANTIGEN AND E ANTIGEN INHIBITOR</b> , United Kingdom Patent No. 1371373, based on European Patent No. 1371373, previously European App'l No. 02702211.0, Filed September 25, 2003, which is a continuation-in-part of Int'l App'l No. PCT/CN02/00128, filed February 28, 2002, which claims priority of Chinese App'l. No. 01104367.9, filed February 28, 2001
6 792-PCT-EP-HK	<b>RECOMBINATION SUPER COMPOUND INTERFERON USED AS HEPATITIS B SURFACE ANTIGEN AND E ANTIGEN INHIBITOR</b> , Hong Kong Patent Number HK1061201, previously Hong Kong App'l No. 04104296.9, Filed June 15, 2004, based on European App'l No. 02702211.0, filed September 25, 2003, which is a continuation-in-part of Int'l App'l No. PCT/CN02/00128, filed February 28, 2002, which claims priority of Chinese App'l No. 01104367.9, filed February 28, 2001
7 792-PCT-JP	<b>RECOMBINATION SUPER COMPOUND INTERFERON USED</b>

		<b>AS HEPATITIS B SURFACE ANTIGEN AND E ANTIGEN INHIBITOR</b> , Japanese Patent No. 4617058, previously Japanese Patent Appl No. 2002-578997, Filed August 28, 2003, corresponding to Int'l App'l No. PCT/CN02/00128, filed February 28, 2002, which claims priority of Chinese App'l No. 01104367.9, filed February 28, 2001
8	792-PCT-SG	<b>RECOMBINATION SUPER COMPOUND INTERFERON USED AS HEPATITIS B SURFACE ANTIGEN AND E ANTIGEN INHIBITOR</b> , Singaporean Grant No. 98954, previously Singaporean App'l No. 200304969-9, Filed August 28, 2003, corresponding to Int'l App'l No. PCT/CN02/00128, Filed Feb. 28, 2002, which claims priority of Chinese App'l No. 01104367.9, filed Feb. 28, 2001
9	792-A-MY	<b>RECOMBINANT SUPER-COMPOUND INTERFERON</b> , Malaysian Patent No. MY-141751-A, previously Malaysian Patent App'l No. P1 20033246, Filed August 28, 2003, which is a continuation-in-part of Int'l App'l No. PCT/CN02/00128, filed February 28, 2002, which claims priority of Chinese App'l No. 01104367.9, filed February 28, 2001
10	792-A-TW	<b>RECOMBINANT SUPER-COMPOUND INTERFERON</b> , Taiwanese Patent I328011, previously Taiwanese App'l No. 92123846, Filed August 28, 2003, which is a continuation-in-part of Int'l App'l No. PCT/CN02/00128, filed February 28, 2002, which claims priority of Chinese App'l No. 01104367.9, filed February 28, 2001
11	792-BA-IN	<b>RECOMBINANT SUPER-COMPOUND INTERFERON PREPARATION AND USES THEREOF</b> , Indian Patent No. 227322, previously Indian Patent Application No. 279/MUM/2004, Filed March 5, 2004, which is a continuation-in-part application of U.S. Serial No. 60/498,785, filed August 28, 2003, and U.S. Serial No. 60/498,923, filed August 28, 2003
12	792-BB-IN	<b>RECOMBINANT SUPER-COMPOUND INTERFERON PREPARATION AND USES THEREOF</b> , Indian Patent No. 243373, previously Indian Patent Application No. 280/MUM/2004, Filed March 5, 2004, which is a continuation-in-part application of U.S. Serial No. 60/498,785, filed August 28, 2003, and U.S. Serial No. 60/498,923, filed August 28, 2003
13	792-B-PCT-AU	<b>RECOMBINANT SUPER-COMPOUND INTERFERON</b> , Australian Patent No. 2003248419, previously Australian Patent App'l No. 2003248419, Filed September 26, 2003, which is a continuation-in-part of Int'l App'l No. PCT/CN02/00128, filed February 28, 2002, which claims priority of Chinese App'l No. 01104367.9, filed February 28, 2001
14	792-A-PCT-US	<b>RECOMBINANT SUPER-COMPOUND INTERFERON</b> , U.S. Patent No. 7,364,724, previously U.S. Serial No. 10/650,365, Filed August 28, 2003, which is a continuation-in-part of Int'l App'l No. PCT/CN02/00128, filed February 28, 2002, which claims priority of Chinese Application No. 01104367.9, filed February 28, 2001
15	792-A2-PCT-US	<b>RECOMBINANT SUPER-COMPOUND INTERFERON</b> , U.S. Patent No. 8,425,896, previously U.S. Serial No. 13/019,044, filed February 1, 2011, continuation application of U.S. Serial No. 12/105,455, filed April

431 277

		18, 2008, continuation application of U. S. Serial No. 10/650,365, filed August 28, 2003, continuation-in-part application of International Application No. PCT/CN02/00128, filed February 28, 2002, which claims priority of Chinese Application No. 01104367.9, filed February 28, 2001
16	792-AB-PCT-US	<b>RECOMBINANT SUPER-COMPOUND INTERFERON</b> , U.S. Patent No. 8,114,395, previously U.S. Serial No. 12/105,455, Filed April 18, 2008, continuation application of U.S. Serial No. 10/650,365, filed August 28, 2003, continuation-in-part application of International App'l No. PCT/CN02/00128, filed February 28, 2002, which claims priority of Chinese Application No. 01104367.9, filed February 28, 2001

431 277